🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Turkey / NCT07739004
Recruiting Observational

Triage Performance and Physiological Predictors of Serious Illness in Febrile Children in the Pediatric Emergency Department

NCT07739004 · tracked via the Priya Life Science Turkey tracker
Phase
Observational
Started
2026-07-28
Last updated
2026-08-05

Condition(s) studied

FeverTriagePediatric Emergency MedicineSerious Bacterial InfectionSepsis

Investigational drug(s) / intervention(s)

Ministry of Health three-level color-coded triage

Ministry of Health three-level color-coded triage: At presentation, each child is assigned a triage category (Red, Yellow, or Green) by the triage nurse using the Turkish Ministry of Health three-level color-coded system, and physiological parameters (heart rate, respiratory rate, oxygen saturation, capillary refill time, AVPU level of consciousness, and general appearance) are recorded on a standardized triage form. This reflects routine care and is not modified for the study.

Study summary

This multicenter prospective observational cohort study evaluates how well the initial triage category assigned by the Turkish Ministry of Health three-level color-coded triage system (Red-Yellow-Green) predicts serious clinical outcomes in children aged 0-18 years who present with fever to pediatric emergency departments. The study additionally assesses whether physiological parameters recorded at triage (heart rate, respiratory rate, oxygen saturation, capillary refill time, AVPU level of consciousness, and general appearance) provide independent and incremental prognostic value beyond the assigned triage category. Ten centers across Turkey will enroll consecutive eligible febrile children over a 3-month period. Routine clinical care and triage decisions are not altered by the study. The primary outcome is a composite serious clinical outcome. The study is reported in accordance with the STROBE and TRIPOD statements.

Eligibility

Sex
ALL
Min age
0 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria: * Age 0-18 years * Presentation to the pediatric emergency department * Fever \>=38.0 C at triage OR history of fever within the preceding 24 hours Exclusion Criteria: * Presentation due to trauma * Elective visits * Missing triage data * Re-attendance within 72 hours for the same episode (only the first visit is included)

Primary outcome measure(s)

Trial sites (10)

FacilityCityRegionStatus
Erciyes University Faculty of Medicine Kayseri Talas Recruiting
Adana City Training and Research Hospital Adana Turkey (Türkiye) Recruiting
Cukurova University Faculty of Medicine Adana Turkey (Türkiye) Recruiting
Akdeniz University Faculty of Medicine Antalya Turkey (Türkiye) Recruiting
Osmangazi University Faculty of Medicine Eskişehir Turkey (Türkiye) Recruiting
Kartal Dr. Lutfi Kirdar City Hospital Istanbul Turkey (Türkiye) Recruiting
Dokuz Eylul University Faculty of Medicine Izmir Turkey (Türkiye) Recruiting
Kayseri City Hospital Kayseri Turkey (Türkiye) Recruiting
Celal Bayar University Faculty of Medicine Manisa Turkey (Türkiye) Recruiting
Tokat University Faculty of Medicine Tokat Province Turkey (Türkiye) Recruiting

More TC Erciyes University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07739004 on ClinicalTrials.gov ↗ ← All trials in Turkey